Mylan's (MYL) Steps on EpiPen Do Not Go Far Enough - Wells Fargo's Maris
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Mylan's (MYL) EpiPen Saga Could Add More Supply Chain Volatility Moving Forward - Evercore
August 25, 2016 11:46 AM EDTEvercore ISI affirms Mylan (Nasdaq: MYL) with a Hold rating and $49 price target amid today's EpiPen cost-adjustment news.
The firm commented, Thanks to our top rated Specialty Pharma guru Umer Raffat (and CNBC) we are highlighting a slide Mylan is featuring (see below) in its... More
Mylan (MYL) calls active after cutting patient cost of EpiPen Auto-Injectors
August 25, 2016 10:03 AM EDTMylan (NASDAQ: MYL) September 46 and 49 calls are active on total call volume of 6K contracts (4K puts) after cutting the patient cost of EpiPen Auto-Injectors. August weekly call option implied volatility is at 68, September is at 36, October is at 34; compared to its 52-week range of 27 to 59.
... MoreMylan (MYL) CEO says healthcare bubble 'going to burst'
August 25, 2016 8:37 AM EDTMylan (NASDAQ: MYL) CEO says healthcare bubble 'going to burst'.
... MoreMylan (MYL) volatile amid CEO interview on CNBC
August 25, 2016 8:34 AM EDTMylan (NASDAQ: MYL) volatile amid CEO interview on CNBC. Last up 3.5%.
... MoreMylan (MYL) Announces Actions to Expand EpiPen Access; Includes Plans to Reduce Patient Cost
August 25, 2016 7:01 AM EDTMylan N.V. (Nasdaq: MYL) announced it is taking immediate action to further enhance access to EpiPen® (epinephrine injection, USP) Auto-Injector by expanding already existing programs in recognition of those patients who are facing the burden of higher out-of-pocket costs. The company is reducing the patient cost of EpiPen® Auto-Injector through the use of a savings card which will cover up to $300 for their EpiPen 2-Pak®. For patients who were previously paying the full amount of the company's list price for EpiPen®, this effectively reduces their out-of-pocket cost exposure by 50%. Mylan also is doubling... More
